Lycia Therapeutics Files for Nasdaq IPO

Lycia Therapeutics, a clinical-stage biotech developing drugs that degrade disease-causing extracellular proteins, has filed for an initial public offering to list on the Nasdaq Global Market under the ticker LYCA. Proceeds are intended to fund clinical programs in allergic diseases and Graves' disease.